Single-particle cryo-electron microscopy has become a widely adopted method in structural biology due to many recent technological advances in microscopes, detectors and image processing. Before being able to inspect a biological sample in an electron microscope, it needs to be deposited in a thin layer on a grid and rapidly frozen. The VitroJet was designed with this aim, as well as avoiding the delicate manual handling and transfer steps that occur during the conventional grid-preparation process. Since its creation, numerous technical developments have resulted in a device that is now widely utilized in multiple laboratories worldwide. It features plasma treatment, low-volume sample deposition through pin printing, optical ice-thickness measurement and cryofixation of pre-clipped Autogrids through jet vitrification. This paper presents recent technical improvements to the VitroJet and the benefits that it brings to the cryo-EM workflow. A wide variety of applications are shown: membrane proteins, nucleosomes, fatty-acid synthase, Tobacco mosaic virus, lipid nanoparticles, tick-borne encephalitis viruses and bacteriophages. These case studies illustrate the advancement of the VitroJet into an instrument that enables accurate control and reproducibility, demonstrating its suitability for time-efficient cryo-EM structure determination.

Eukaryotic TIR (Toll/interleukin-1 receptor protein) domains signal via TIR–TIR interactions, either by self-association or by interaction with other TIR domains. In mammals, TIR domains are found in Toll-like receptors (TLRs) and cytoplasmic adaptor proteins involved in pro-inflammatory signaling. Previous work revealed that the MAL TIR domain (MALTIR) nucleates the assembly of MyD88TIR into crystalline arrays in vitro. A microcrystal electron diffraction (MicroED) structure of the MyD88TIR assembly has previously been solved, revealing a two-stranded higher-order assembly of TIR domains. In this work, it is demonstrated that the TIR domain of TLR2, which is reported to signal as a heterodimer with either TLR1 or TLR6, induces the formation of crystalline higher-order assemblies of MyD88TIR in vitro, whereas TLR1TIR and TLR6TIR do not. Using an improved data-collection protocol, the MicroED structure of TLR2TIR-induced MyD88TIR microcrystals was determined at a higher resolution (2.85 Å) and with higher completeness (89%) compared with the previous structure of the MALTIR-induced MyD88TIR assembly. Both assemblies exhibit conformational differences in several areas that are important for signaling (for example the BB loop and CD loop) compared with their monomeric structures. These data suggest that TLR2TIR and MALTIR interact with MyD88 in an analogous manner during signaling, nucleating MyD88TIR assemblies uni­directionally.

This work describes the X-ray structure of orange–red crystals of 2-meth­oxy-5-nitro­aniline, C7H8N2O3. The compound displays concentration-dependent UV-Vis spectra, which is attributed to dipole-induced aggregation, and light absorption arising from an inter­molecular charge-transfer process that decreases in energy as the degree of aggregation increases. The crystals display π-stacking where the dipole moments align anti­parallel. Stacked mol­ecules inter­act with the next stack via hydrogen bonds, which is a state of maximum aggregation. Light absorption by charge transfer can be compared to colored inorganic semiconductors such as orange–red CdS, with a band gap of 2.0–2.5 eV.

A host–guest supra­molecular inclusion complex was obtained from the co-crystallization of A1/A2-bromo­but­oxy-hy­droxy difunctionalized pillar[5]arene (PilButBrOH) with adipo­nitrile (ADN), C47H53.18Br0.82O10·C6H8N2. The adipo­nitrile guest is stabilized within the electron-rich cavity of the pillar[5]arene host via multiple C—H⋯O and C—H⋯π inter­actions. Both functional groups on the macrocyclic rim are engaged in supra­molecular inter­actions with an adjacent inclusion complex via hydrogen-bonding (O—H⋯N or C—H⋯Br) inter­actions, resulting in the formation of a supra­molecular dimer in the crystal structure.

The major principles and requirements of asymmetric and inclined double-crystal monochromators are re-examined and presented to guide their design and development for significantly reducing heat load density and gradient on the monochromators of fourth-generation synchrotron light sources and X-ray free-electron lasers.

High-repetition-rate free-electron lasers impose stringent requirements on the thermal deformation of beamline optics. The Shanghai HIgh-repetition-rate XFEL aNd Extreme light facility (SHINE) experiences high average thermal power and demands wavefront preservation. To deeply study the thermal field of the first reflection mirror M1 at the FEL-II beamline of SHINE, thermal analysis under a photon energy of 400 eV was executed by fluid and solid heat transfer method. According to the thermal analysis results and the reference cooling water temperature of 30 °C, the temperature of the cooling water at the flow outlet is raised by 0.15 °C, and the wall temperature of the cooling tube increases by a maximum of 0.5 °C. The maximum temperature position of the footprint centerline in the meridian direction deviates away from the central position, and this asymmetrical temperature distribution will directly affect the thermal deformation of the mirror and indirectly affect the focus spot of the beam at the sample.

Source: Scott Searle 11/08/2024

Gogo Inc. (GOGO:NASDAQ) reported its Q3/24 financial results, and they slightly exceeded expectations, reported Scott Searle, managing director at Roth MKM, in a Nov. 5 research note.

The company provides in-flight connectivity services to business aviation markets through its North American terrestrial air-to-ground network.

137% Potential Return

Roth maintained its target price of US$15.50 per share on Gogo, noted Searle.

"We believe this provides a reasonable 12-plus-month target given the expected impact from two major new product cycles as we enter 2025," he wrote, referring to Galileo, the company's global inflight broadband service, and its 5G product line.

In comparison, the company's share price at the time of the report was about US$6.55 per share. From this price, the return to target reflects 137% upside.

Gogo remains a Buy.

Quarter's Highlights

Searle reported that Gogo's Q3/24 service revenue was a beat. At US$81.9 million (US$81.9M), it was slightly higher than that in Q2/24 and driven by modestly better-than-expected aircraft online, Searle reported. This revenue exceeded Roth's estimate by about US$300,000.

Also of note, Galileo is on track to launch in Q4/24, and Gogo continues to grow its portfolio of supplemental type certificates and partners around the world.

A Look Ahead

Gogo's outlook for 2024 of US$400-410M encompasses consensus' estimate, noted Searle. The company, though, has "pulled long-term guidance ahead of the Satcom Direct [acquisition] closing."

Roth expects Galileo and 5G will lead recovery, expected in late 2025.

In other news, noted Searle, Gogo Chairman and Chief Executive Officer Oakleigh Thorne will present at Roth's NYC Tech Event on Nov. 20.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Roth MKM, Gogo Inc., November 5, 2024

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures: ROTH makes a market in shares of Gogo, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2024. Member: FINRA/SIPC.

( Companies Mentioned: GOGO:NASDAQ, )

Full Text:

What an animal eats is a fundamental aspect of its biology, but surprisingly, the evolution of diet had not been studied across the animal kingdom until now. Scientists at the University of Arizona report several unexpected findings from taking a deep dive into the evolutionary history of more than one million animal species and going back 800 million years, when the first animals appeared on our planet. The study revealed several surprising key insights: Many species living today that are carnivorous, meaning they eat other animals, can trace this diet back to a common ancestor more than 800 million years ago; A plant-based, or herbivorous, diet is not the evolutionary driver for new species that it was believed to be; Closely related animals tend to share the same dietary category -- plant-eating, meat-eating, or both. This finding implies that switching between dietary lifestyles is not something that happens easily and often over the course of evolution.

Image credit: Daniel Stolte/UANews

People rest while riding a Los Angeles Metro Rail train amid the coronavirus pandemic on April 1, 2020 in Los Angeles, California.; Credit: Mario Tama/Getty Images

Despite the racial reckoning going on in America right now, and despite the fact that attitudes towards race, inclusion and representation are different now than they were 30 years ago, new research from UC Berkeley shows that a large majority of American metro areas are more segregated now than they were in 1990. The new report from Berkeley’s Institute covers a number of topic areas, but among the key findings were from the national segregation report component of the project, which found Los Angeles to be the sixth-most segregated metro area with more than 200,000 people.

Today on AirTalk, we’ll talk with the lead researcher on the new report and a local historian to talk about how we see the findings of the report play out in Southern California.

Guests:

Stephen Menendian, assistant director and director of research at the Othering & Belonging Institute at UC Berkeley, which works to identify and eliminate the barriers to an inclusive, just, and sustainable society in order to create transformative change; he tweets @SMenendian

Eric Avila, professor of history, urban planning, and Chicano/a studies at UCLA

This content is from Southern California Public Radio. View the original story at SCPR.org.

Athletes compete during the cycling portion of the IRONMAN 70.3 Steelhead on June 27, 2021 in Benton Harbor, Michigan. ; Credit: Patrick McDermott/Getty Images for IRONMAN

Whether you’re new to running or you’ve finished your tenth triathlon, we want to hear from you about what motivates you and how that translates into pushing yourself physically. 

Guests: 

Mark Remy, longtime runner and writer in Portland, Oregon; creator of humor website dumbrunner.com; he is the author of many books, including The Runner's Rule Book: Everything a Runner Needs to Know--And Then Some (Runner's World) (Rodale Books, 2009)

Sharon McNary, infrastructure correspondent at KPCC; she finished her 11th Ironman Race last week at Coeur d’Alene; she tweets @KPCCsharon

This content is from Southern California Public Radio. View the original story at SCPR.org.

The Solar System is full of its own tricks and treats, so discover some of our favorites below.

Restoration of the imperiled sagebrush biome will require tools that assist resource managers in determining which restoration practices are most effective, and when and where restoration efforts will lead to the most ecosystem recovery. New research from USGS and Colorado State University provides biome-wide insights and spatially explicit tools that can inform restoration practices. 

Comedian Paul Mooney takes part in a discussion panel after the world premiere screening of "That's What I'm Talking About" at The Museum of Television & Radio January 30, 2006 in New York City.; Credit: Paul Hawthorne/Getty Images

In the past couple of weeks, we’ve lost several industry icons, including Paul Mooney, Charles Grodin and Norman Lloyd. 

Actor and comedian Paul Mooney was a boundary-pushing comedian who was Richard Pryor’s longtime writing partner and whose bold, incisive musings on racism and American life made him a revered figure in stand-up. He was 79. Charles Grodin was an offbeat actor and writer who scored as a caddish newlywed in “The Heartbreak Kid” and later had roles ranging from Robert De Niro’s counterpart in the comic thriller “Midnight Run” to the bedeviled father in the “Beethoven” comedies. He was 86. Norman Lloyd’s role as kindly Dr. Daniel Auschlander on TV’s “St. Elsewhere” was a single chapter in a distinguished stage and screen career that put him in the company of Orson Welles, Alfred Hitchcock, Charlie Chaplin and other greats. He was 106. Lloyd’s son, Michael Lloyd, said his father died at his home in the Brentwood neighborhood of Los Angeles. Today on FilmWeek, our critics reflect on their work. Plus they share a couple of their favorite films of the 2021 so far. 

With files from the Associated Press

Guests:

Angie Han, film critic for KPCC and deputy entertainment editor at Mashable; she tweets @ajhan

Wade Major, film critic for KPCC and CineGods.com

Peter Rainer, film critic for KPCC and the Christian Science Monitor

This content is from Southern California Public Radio. View the original story at SCPR.org.

Full Text:

Needle pricks not your thing? A team of National Science Foundation-funded scientists is developing wearable skin sensors that can detect what's in your sweat. They hope that one day, monitoring perspiration could bypass the need for more invasive procedures like blood draws, and provide real-time updates on health problems such as dehydration or fatigue. In a new paper, the team describes a new sensor design that can be rapidly manufactured using a "roll-to-roll" processing technique that essentially prints the sensors onto a sheet of plastic like words on a newspaper. They used the sensors to monitor the sweat rate, and the electrolytes and metabolites in sweat, from volunteers who were exercising, and others who were experiencing chemically induced perspiration. The new sensors contain a spiraling microscopic tube, or microfluidic, that wicks sweat from the skin. By tracking how fast the sweat moves through the microfluidic, the sensors can report how much a person is sweating, or their sweat rate. The microfluidics are also outfitted with chemical sensors that can detect concentrations of electrolytes like potassium and sodium, and metabolites like glucose.

Image credit: Bizen Maskey/Sunchon National University

Source: Streetwise Reports 10/28/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) and its Cell Pouch technology could be the solution to existing challenges involving the delivery of medical treatments to patients, such as the ones described here.

Diabetic patients in resource-limited settings are having to revert back to one of the less favored, alternative ways to take insulin, via syringes or glass vials, because Danish pharmaceutical company, Novo Nordisk A/S (NVO:NYSE), will stop making its insulin pens, The Guardian reported. Patients generally prefer this method for dosing themselves with insulin, as shown in a 2024 survey, because it is more convenient and more accurate.

Type 1 diabetic patients already are being impacted as Novo stopped supplying its insulin pens to certain regions, South Africa for instance. Patients there have switched back to using glass vials.

In a second situation, Novo Nordisk is working to bring stem cell-based therapies to patients more efficiently and, in seeking a solution, formed a partnership with Evotec SE (EVO:NASDAQ) to develop technologies that will achieve this, noted Evotec is a Germany-based global biotech firm with its own cell therapy and partnered cell types all in preclinical development for various indications, including diabetes, oncology, cardiology, and ophthalmology.

Per the agreement, Novo Nordisk is to provide research and development funding and potentially monetary incentives to Evotec, and Evotec is to develop the desired new technologies. Novo has the option to obtain exclusive rights to use, in a predefined medical indication, the product(s) born out of this collaboration agreement. Novo's areas of focus, along with diabetes, are cardiovascular diseases, rare diseases, growth hormone-related diseases, hemophilia, nonalcoholic steatohepatitis, and weight management.

Safe, Effective Therapeutic Cell Delivery

Sernova Corp.'s Cell Pouch is a vehicle for delivering various types of therapeutic cells to patients, such as donor islet cells to insulin-dependent diabetics.

When used, the Cell Pouch's containment channels are filled with the appropriate therapeutic cells, and then the device is implanted in the patient. In situ, the cells release therapeutic proteins or hormones the patient's body completely or partially lacks. The device creates a vascularized, organ-like environment that protects the therapeutic cells from immune system attacks, keeping them alive and functioning.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a Sept. 12 research report.

Sernova is testing its Cell Pouch in the clinic, specifically in Type 1 diabetes. In its ongoing Phase 1/2 study, the Canadian company is evaluating the treatment of insulin-dependent diabetes with donor islets implanted via the Cell Pouch, with added immunosuppression therapy. Study data so far have shown the Cell Pouch to be safe and well tolerated and the treatment, effective, reported Dr. Joseph Pantginis, analyst at H.C. Wainwright & Co., in a Sept. 12 research report.

Seven patients, all six of Cohort A and one in Cohort B, achieved sustained insulin independence, between 5.5 and 50 months in duration, free of hypoglycemic episodes. Their blood sugar levels were controlled in the nondiabetic range (i.e.,) HbA1c less than 6.5%.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote.

A Cell Pouch removed from one of the study patients showed it still contained functioning insulin, glucagon, and somatostatin-producing cells. No evidence was seen of detrimental fibrotic tissue, too many T-cells, material degradation, or changes in the device architecture.

"We believe the impressive response rates and observed durability support Sernova's strategy and justify further investigation while positioning the technology for potential commercial success," noted Pantginis.

The results add to an expanding collection of evidence that the Cell Pouch is functioning as it should. The data also support the "impressive" results already reported from this study and help derisk future related trials.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund in a Sept. 16 note.

In another of its programs, Sernova, in collaboration with Evotec, is developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Maund reported.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," he added.

This partnership was announced on May 17, 2022. You can read more about it in the press release here.

Market Growth Predicted to 2030

The global live cell encapsulation market, encompassing drug delivery, regenerative medicine and cell transplantation, is expected to continue growing through at least 2030, according to Grand View Research. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, The market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Several factors are expected to keep driving market growth during the forecast period, Grand View noted. A significant one is the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

The advantages of live cell encapsulation in controlled drug delivery are boosting the market, too. They include enhanced therapeutic effects, lowered drug dose, reduced cytotoxicity, improved patient convenience and better patient compliance.

Novel new products and technological advancements are expected to add value to the market as well.

The Catalysts: Progress With Programs

Various potential stock-moving events are slated for Sernova, according to its September 2024 Corporate Presentation.

Two catalysts are expected by Sernova in 2025, related to the company's ongoing Phase 1/2 clinical trial in Type 1 diabetes. One is results for the remaining Cohort B patients. The other is commencement of Cohort C, who will receive, along with the islet cells, an optimized immune suppression regimen.

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

Next year, Sernova plans to start a Phase 1/2 trial of the regeneratively produced islet cells to result from its partnership with Evotec, delivered via the Cell Pouch to Type 1 diabetes patients.

Other catalysts are expected to come as a result of Sernova advancing its preclinical programs. One is a personalized treatment with patient corrected cells via Cell Pouch for hypothyroidism. Another is a Cell Pouch-delivered, ex vivo lentiviral factor VIII gene therapy for hemophilia, being developed in partnership with the European Haemacure Consortium.

Also, through partnerships, Sernova is developing technologies that would eliminate the need for concurrent immunosuppression during Cell Pouch-delivered cell treatment, a "blue sky objective," Douglas Loe, a Leede Financial Inc. analyst, noted in a Sept. 12 research report.

"Any advances in this regard could be incorporated into future Cell Pouch studies," he wrote. "We do not consider the need for such therapy to be relevant to Cell Pouch function itself."

Analyst: Company is "Very Undervalued"

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

According to H.C. Wainwright's Pantginis, the deepening responses of Type 1 diabetes patients in its Phase 1/2 trial continue to "crystallize Sernova stock's possible upside." The upside reflected in Pantginis' price target is 2,122%. The analyst recommends the company as a Buy.

Ventum's Quenneville also has a Buy on Sernova, and his target price reflects an 826% return on investment. In his report, the analyst highlighted the impressive efficacy and tolerability of the Cell Pouch up to five years post-implantation, as shown in the Phase 1/2 clinical trial data.

"This represents the longest-lasting implanted encapsulation device containing functioning islets without fibrosis," Quenneville wrote.

According to Technical Analyst Maund, Sernova is "very undervalued here given its huge potential" in the Type 1 diabetes market, as indicated on the stock charts. The fundamental outlook for the company is improving, and evidence is strong that a reversal to the upside may be happening. SVA may appreciate significantly soon. [OWNERSHIP_CHART-4790]

"Sernova is therefore viewed as a good stock to accumulate in this area, between the current price and recent lows," Maund wrote on Sept. 16. At that time, Sernova's share price was about the same as it is now.

Ownership and Share Structure

According to Refinitiv, about 12.96% of the company is held by insiders and management, and 0.05% by institutions. The rest is retail.

Top shareholders include Tomas Angel with 4.91%, Director Steven Sangha with 4.27%, Betty Anne Millar with 1.32%, Brett Alexander Whalen with 0.87%, and Garry Deol with 0.77%.

Its market cap is CA$83 M. Its 52-week range is CA$0.20−0.82 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

Source: Dr. Douglas Loe 10/31/2024

Leede Financial analysts Dr. Douglas Loe and Siew Ching Yeo, in a research report published on October 30, 2024, maintained their Speculative Buy rating on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) with a price target of US$9.50. The report follows ProMIS's presentation of interim Phase I data for PMN310, its Alzheimer's disease (AD) candidate, at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

The analysts highlighted the positive safety and pharmacokinetic (PK) data, stating, "We were encouraged (though not overly surprised) to see that the mAb was well-tolerated at all five test doses ranging from 2.5mg/kg-to-40mg/kg." They added, "PK analysis of all of these patient cohorts in this single-ascending dose (SAD) trial suggests that once-monthly dosing may be sufficient to sustain mAb levels both in plasma and in cerebrospinal fluid over time."

Regarding dosing efficacy, the analysts noted, "Importantly, ProMIS indicated in the Jul/24 update that even at 2.5mg/kg dosing, PMN310 levels in CSF were over 100x higher than predicted to be necessary to bind to all beta-amyloid oligomers that could accumulate in CSF in diseased patients."

The analysts emphasized the significance of recent industry developments, particularly AbbVie's acquisition of Aliada Therapeutics, stating, "AbbVie's tangible interest in Phase I-stage AD assets shows us that ProMIS could itself be attractive to future suitors if/when it can document direct impact on cognitive impairment in diseased patients."

The report highlighted ProMIS's financial position following its recent equity offering, noting that the company raised US$30.3M with multiple layers of warrant coverage tied to development milestones.

Leede Financial's valuation methodology combines multiple approaches. The analysts explained, "We are maintaining our Speculative Buy rating and one-year PT of US$9.50 on PMN, with our valuation still based on NPV (30% discount rate) and multiples of our F2029 EBITDA/fd EPS forecasts."

They added, "By direct comparison to Aliada's US$1.4B value, PMN shares would notionally be valued on a fully-diluted basis at US$17.65/shr."

In conclusion, Leede Financial's maintenance of their Speculative Buy rating and US$9.50 price target reflects confidence in ProMIS's development of PMN310 and its potential in the Alzheimer's disease market. The share price at the time of the report of US$1.03 represents a potential return of approximately 822% to the analysts' target price, highlighting the significant upside potential if the company's clinical development plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences Inc.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., ProMIS Neurosciences Inc., October 30, 2024

Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

( Companies Mentioned: PMN:TSX; PMN:NCM, )

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

; Credit: /Katherine Du

Over the years, NPR's poetry community has turned both painful and joyful experiences into magnificent work.

As the world still endures the coronavirus pandemic, the U.S. also grieves over increased violence against Asian Americans and a mass shooting in Georgia that left six women of Asian descent dead.

"Let's be clear: Anti-Asian violence and discrimination are not new. But, this racism seems to be heightened," says Kwame Alexander, NPR's resident poet. "And the onus is not on Asian Americans to figure this out. Frankly, it's on white people, it's on the rest of us — individually, systemically, to talk about it, to pay attention to, advocate against it."

"Between Autumn Equinox and Winter Solstice, Today," by Emily Jungmin Yoon, is a list poem that reflects the coldness of the world and how it wears on us. Yoon is a South Korean-born poet pursuing her Ph.D. in Korean literature at the University of Chicago.

Alexander and Morning Edition's Rachel Martin ask listeners: How do you cope with recent anti-Asian violence and discrimination? Tell us in a list poem.

Your poem doesn't have to rhyme. It just needs to have an ordered list with details that show your state of mind — and must begin with the word "today."

Share your poem through the form below. Then Alexander will take lines from some of your pieces and create a community crowdsourced poem. Alexander and Martin will read it on air, and NPR will publish it online, where contributors will be credited.

Submissions are due by noon ET on Monday, April 5.

Here are the terms of the callout:

By providing your Submission to us, you agree that you have read, understand and accept the following terms in relation to the content and information (your "Submission") you are providing to National Public Radio ("NPR," "us" or "our"):

You are submitting content pursuant to a callout by Morning Edition related to a segment with Kwame Alexander wherein he creates unique poetry based on listener submissions. You understand that you are submitting content for the purpose of having Kwame use that content to create a new poem or poems ("Poem") with the material you submit. You must be over the age of 18 to submit material.

You will retain copyright in your Submission, but agree that NPR and/or Kwame Alexander may edit, modify, use, excerpt, publish, adapt or otherwise make derivative works from your Submission and use your Submission or derivative works in whole or in part in any media or format and/or use the Submission or Poem for journalistic and/or promotional purposes generally, and may allow others to do so. You understand that the Poem created by Kwame Alexander will be a new creative work and may be distributed through NPR's programs (or other media), and the Poem and programs can be separately subject to copyright protection. Your Submission does not plagiarize or otherwise infringe any third-party copyright, moral rights or any other intellectual property rights or similar rights. You have not copied any part of your Submission from another source. If your Submission is selected for inclusion in the Poem, you will be acknowledged in a list of contributors on NPR's website or otherwise receive appropriate credit, but failure to do so shall not be deemed a breach of your rights.

Your submission will be governed by our general Terms of Use and Privacy Policy. As the Privacy Policy says, we want you to be aware that there may be circumstances in which the exemptions provided under law for journalistic activities or freedom of expression may override privacy rights you might otherwise have.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The logo of National Oceanic and Atmospheric Administration is seen at the Nation Hurricane Center in Miami on Aug. 29, 2019. President Biden has nominated Rick Spinrad to head NOAA.; Credit: Eva Marie Uzcategui/Getty Images

President Biden is nominating Rick Spinrad to lead the National Oceanic and Atmospheric Administration, the government's premier agency on climate science which oversees the National Weather Service.

Prior to his current role as a professor of oceanography at Oregon State University, Spinrad served as NOAA's top scientist under President Obama and the U.S. representative to the United Nations' Intergovernmental Oceanographic Commission.

The nomination comes at a difficult moment in NOAA's history. The agency has been without an official, Senate-confirmed leader since former President Donald Trump took office in January 2017, after his two nominees to lead the agency failed to garner enough support to win a full vote before the Senate.

If Spinrad manages to win over the Senate, he will have to contend with a challenge beyond the agency's already-rigorous scientific mandate: restoring public confidence in a traditionally apolitical agency marred by political scandal.

In September 2019, then-President Trump wrongly said Alabama was in the projected path of Hurricane Dorian. He continued to reassert the claim for several days, including during an Oval Office briefing on the storm — in which he displayed what appeared to be an official National Weather Service map in which the storm's projected path was extended to Alabama by someone using a black marker.

After a National Weather Service office in Birmingham put out a tweet correctly stating that Alabama would not feel the effects of the storm, NOAA published an unsigned defense of the president's claims and rebuking its professional staff who posted the message.

Dan Sobien, then-president of the National Weather Service Employees Organization, said at the time that "the hard working employees of the NWS had nothing to do with the utterly disgusting and disingenuous tweet sent out by NOAA management."

If confirmed, Spinrad will lead a 12,000-person agency charged with a diverse portfolio that spans daily weather forecasts, climate monitoring, fisheries management and coastal restoration.

In a statement, the Environmental Defense Fund's Eric Schwaab applauded Spinrad's nomination, saying that NOAA's workers "couldn't ask for a better leader to restore scientific integrity and honor the agency's mission."

Biden, whose administration has made climate action a central focus, has proposed the largest budget in NOAA's history — $6.9 billion, a $1.5 billion increase over the 2021 budget allocated by Congress. It remains to be seen whether Congress will agree to the increase.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Gloria Majiga-Kamoto, an activist from Malawi, is one of six recipients of the 2021 Goldman Environmental Prize. Majiga-Kamoto has been instrumental in implementing Malawi's ban on thin plastics.; Credit: /Goldman Environmental Prize

For Gloria Majiga-Kamoto, her great awakening to plastic pollution started with goats.

She was working for a local environmental NGO in her native Malawi with a program that gave goats to rural farmers. The farmers would use the goat's dung to produce low-cost, high-quality organic fertilizer.

The problem? The thin plastic bags covering the Malawian countryside.

"We have this very common street food, it's called chiwaya, and it's just really potato fried on the side of the road and it's served in these little blue plastics," Majiga-Kamoto says. "So because it's salty, once the goats get a taste of the salt, they just eat the plastic because they can't really tell that it's inedible. And they die because it blocks the ingestion system — there's no way to survive."

The goats were supposed to reproduce for the program, with the goat kids going on to new farmers. But because of plastic deaths the whole goat chain started falling apart.

"It was a lot of expectation from the farmers waiting to benefit. So you had this farmer who had this one goat and then they lost it. And that means that in that chain of farmers, that's obviously affected quite a number of farmers who won't get their turn."

For Majiga-Kamoto, her experience at the NGO with the plastic-eating goats was the moment it all changed. All of a sudden she started noticing how plastics were everywhere in the Malawian environment and food system — affecting people's livelihoods and health.

The fish in Lake Malawi were eating plastic trash. The country's cows were eating plastic. Researchers found that in one Malawi town 40% of the livestock had plastic in their intestines.

"We're choking in plastics," Majiga-Kamoto says, "And so what it means is that in one way or the other, we as humans are consuming these plastics."

Majiga-Kamoto was also seeing how plastics contributed to the growth of disease. Huge piles of plastic trash were blocking off Malawi's many waterways, creating pungent breeding grounds for mosquitoes that carry malaria and for bacteria that cause cholera.

The 30-year-old says she remembers a time when Malawians didn't rely so much on thin, single-use plastic. "I remember back in the day when we'd go to the market and buy things like fish, like dried fish, you'd get it in newspapers."

But thin plastics have taken off in the last decade or so as new manufacturers sprung up in Malawi, selling products like thin plastic bags at cheap prices that made them affordable and accessible even in the most undeveloped parts of the country. A 2019 UNDP funded report found that Malawi produces an estimated 75,000 tonnes of plastic a year, with 80% reportedly single-use plastic. Single-use plastic refers to bags, straws and bottles that can't be recycled, and thin plastic refers to plastic that's under 60 microns in thickness.

The proliferation of this thin plastic waste led to the Malawian government's 2015 decision to ban the production, distribution and importation of single-use thin plastic. But before the ban could go into full effect, Malawi's plastics manufacturing industry filed an injunction at the country's High Court. The ban stalled.

When Majiga-Kamoto and a group of her fellow environmental NGO-workers and activists heard about the injunction they were angry and frustrated. "It sort of caught our interest to say, 'Wait a minute, you mean that there's actually people in our society who think that this is not a problem and that we should actually continue to live this way?'"

Galvanized, Majiga-Kamoto led a group of local environmental activists and NGOs to actually implement the single-use plastics ban, organizing marches on the judiciary where the decision would be decided. She kept her job at her NGO, the Centre for Environmental Policy and Advocacy, and did this work on her own time.

She rejected the plastic industry's argument that the ban would hurt Malawi's economy — and even debated an industry lobbyist on TV.

Finally in 2019, after multiple injunctions filed by the plastics industry, the High Court ruled in favor of the single-use thin plastic ban. The following year the Malawian government began closing down illegal plastic manufacturers.

Last week Majiga-Kamoto was named one of the six winners of the 2021 Goldman Environmental Prize for her work on this issue. Michael Sutton, executive director of the Goldman Environmental Foundation, says Majiga-Kamoto's fight with the plastic lobby epitomizes the spirit of the prize. "She mustered the troops, the grassroots communities, to take on the government and big industry and won several times," Sutton says, "She not only won the ban in law, but is now holding the government's feet to the fire to enforce it."

And Majiga-Kamoto isn't letting up her pressure to uphold the single-use plastic ban anytime soon. Although she is trying to get some summer vacation time with her family — that is, if she isn't interrupted.

"I was just at the lake a couple of weeks ago and we were there just enjoying the beautiful lake and along come these pieces of plastic." Three plastic bags floated up closer to her, her son and her niece as they played in the water.

Majiga-Kamoto grabbed for the bags.

"My family was laughing to say, 'You shouldn't be working! You're at the lake!' And I'm like, 'But I can't just leave them in there!'"

Julia Simon is a regular contributor to NPR's podcasts and news desks focusing on climate change, energy, and business news.

This content is from Southern California Public Radio. View the original story at SCPR.org.

For the last month, Frank Galaviz has wondered when running water will return to his town.

The 77-year-old resident of Teviston — a small rural community in Central California — has been forced to depend on stored and bottled water after the pump in the town's only functioning well broke down in early June. Since then, residents have had to travel to neighboring towns to shower or depend on the town's water storage tanks for their daily needs.

Temperatures continue to reach into triple digits as a brutal heat wave sweeps across the West Coast. The ongoing drought only exacerbates the problem, Galaviz says.

"[My wife and I] have lived through many challenges," he says. "We both have survived cancer, but we will not be able to survive without water. This is a problem that is not going away."

Teviston sits between the cities of Fresno and Bakersfield in the San Joaquin Valley and is home to mostly Latino farmworkers. Normal days in town are usually slow-paced and idyllic, Galaviz says, with many residents commuting to the nearby towns and cities on business. Now, they leave to find more water.

This is not the first time Galaviz or his neighbors have struggled with a broken well. He says two other wells had broken down in previous years and had not been repaired. A new, more modern well is in the works, but Galaviz estimates its completion is still a few years off.

The community continues waiting for repair parts to arrive in hopes it will fix the current well's pump, he added, a process that could take a few weeks.

"It is not normal to not be able to flush toilets," he says. "It's not normal to not be able to take a shower."

Residents have managed to come up with a temporary fix, using their water storage tanks to offer relief.

"We were able to get some of the water pressure back," Galaviz said. "We put a submersible pump into one of our old wells and we're forcing water from the storage tanks through that system. But it's not a permanent fix."

Rural Latino communities in California have been particularly vulnerable to drought conditions, according to a report from the state Legislative Analyst's Office.

"Having no water equals bad health," state Sen. Melissa Hurtado, who serves California's 14th District, tells Weekend Edition. Hurtado says her bill, SB 559, would allot $785 million to fund and repair water supply infrastructure. One of the waterways posed for fixing is the Friant-Kern canal, which supplies Teviston and the towns around it. Over the years, the canal has become subject to subsidence — a condition that has caused some parts of the canal to sink and means it can't deliver as much water.

"SB 559 would help fix the canal so that the basin and the communities that rely on water here would be able to have more access to it," Hurtado says.

Galaviz has spent the last few weeks knocking on doors to check in on neighbors and trying to organize help.

"I have a neighbor whose daughter has medical problems. She needs drinking water, pure water," he says. "It hurts to see people suffering."

Hafsa Fathima and Jan Johnson produced and edited the audio story.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Crews searching the building collapse site in Surfside, Fla., have discovered four more victims since Monday, bringing the death toll to 32. Authorities have identified 26 of the bodies.

Another 113 people were unaccounted for, though local officials said they had only been able to confirm that about 70 of those people were in the building at the time of the collapse nearly two weeks ago.

Detectives are continuing to follow up on reports submitted about possible victims in the partial collapse, but in some cases they have been unable to reach those who submitted the tips in the first place.

"People call anonymously. People call and don't leave return phone numbers. People call with partial information, not enough to really secure whether that person may or may not have been in the building," Miami-Dade County Mayor Daniella Levine Cava told reporters on Tuesday.

Some of the reports of possible victims are also incomplete, she said, including a name but no apartment number or no date of birth.

Levine Cava urged people who are missing loved ones to communicate with local authorities. She said there may also be victims of the collapse who have not been reported missing.

The rescue effort stopped briefly overnight due to lightning from a passing storm. Surfside Mayor Charles Burkett said high winds were hampering the cranes moving heavy debris from the collapse site.

Lt. Gov. Jeanette Nuñez said Florida has declared a state of emergency ahead of Tropical Storm Elsa, which is expected to reach hurricane strength before making landfall Wednesday morning on the state's west coast.

This content is from Southern California Public Radio. View the original story at SCPR.org.

RealtyAnalytix Advisors, LLC announces the introduction of Catawba Industrial Commons, a multi-tenant industrial campus offering the most attractive, affordable and functional manufacturing, distribution and warehousing space in the Greater Catawba County region.

The company will locate a manufacturing operation in the Catawba Industrial Commons, creating 110 new jobs with an average wage of over $50,000 and investing $15 million over the next five years. It will provide specialized services for parts used in gas turbine engines produced by Siemens, GE, Alstom and Rolls-Royce.

Area youth participating in the NC Cooperative Extension�s 4-H program helped children at Catawba County Public Health plant vegetable seeds. The activity was one of a series of visits by local North Carolina Cooperative Extension staff and volunteers to Public Health�s Women, Infants and Children (WIC) clinic designed to encourage WIC families to grow and eat fresh vegetables.

Alexander, Burke, Caldwell and Catawba County students in the 4th or 5th grades submitted posters related to the theme �Severe Weather Awareness� and illustrated an example of a natural hazard that affects North Carolina. One poster from each county and one overall winner from all entries were chosen as the winners of the Unifour Area Severe Weather Awareness Week Poster Contest. The winners were announced during Severe Weather Awareness Week with surprise presentations at each winner�s school.

The EcoComplex is a system that recovers all useable products and by-products from a group of private and public partners located in a close-knit defined area. This group of partners works together to use each other�s waste products either as a source of energy (electricity, steam, or heat) or as a raw material for the production of their own product (pallets, lumber, compost, brick shapes/art). The EcoComplex is also focused on making and using �green� energy and on economic development.

As of October 1, 2012, Catawba County EMS has been named a Permanent Car Seat Checking Station by Buckle Up NC. Car seat checks will be conducted Monday thru Friday, from 9:00 a.m. to 4:00 p.m., by appointment, at the Newton EMS base, located at 1101 South Brady Ave, Newton, NC 28658.

Smokers who are exposed to radon appear to be at even greater risk for lung cancer, because the effects of smoking and radon are more powerful when the two factors are combined, says a new report by a committee of the National Research Council.

Reducing one of the nations leading causes of death and injury – medical errors – will require rigorous changes throughout the health care system, including mandatory reporting requirements.

To meet the bodys daily energy and nutritional needs while minimizing risk for chronic disease, adults should get 45 percent to 65 percent of their calories from carbohydrates, 20 percent to 35 percent from fat, and 10 percent to 35 percent from protein.

The value of what the United States loses because of the poorer health and earlier death experienced by the 41 million Americans who lack health insurance is estimated to be $65 billion to $130 billion every year, according to a first-ever economic analysis of the costs of uninsurance for society overall.

Short-term exposure to current levels of ozone in many areas is likely to contribute to premature deaths, says a new National Research Council report, which adds that the evidence is strong enough that the U.S. Environmental Protection Agency should include ozone-related mortality in health-benefit analyses related to future ozone standards.

A new data network that integrates emerging research on the molecular makeup of diseases with clinical data on individual patients could drive the development of a more accurate classification of disease and ultimately enhance diagnosis and treatment, says a new report from the National Research Council.

Research to date on the effect of capital punishment on homicide rates is not useful in determining whether the death penalty increases, decreases, or has no effect on these rates, says a new report from the National Research Council.

One of the nation’s largest surveys of crime victims is likely undercounting incidences of rape and sexual assault, making it difficult to ensure that adequate law enforcement resources and support services are available for victims, says a new report by the National Research Council.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome -- commonly referred to as ME/CFS -- is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, says a new report from the Institute of Medicine.

As immigrants and their descendants become integrated into U.S. society, many aspects of their lives improve, including measurable outcomes such as educational attainment, occupational distribution, income, and language ability, but their well-being declines in the areas of health, crime, and family patterns, says a new report from the National Academies of Sciences, Engineering, and Medicine.

It is now possible to estimate the influence of climate change on some types of extreme events, such as heat waves, drought, and heavy precipitation, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Weather and environmental forecasts made several weeks to months in advance can someday be as widely used and essential as current predictions of tomorrow’s weather are, but first more research and sustained investment are needed, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Across the current military and civilian trauma care systems, the quality of trauma care varies greatly depending on when and where an individual is injured, placing lives unnecessarily at risk, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine that examines the regulations governing federally funded research recommends that Congress authorize and the president appoint an independent national commission to examine and update the ethical, legal, and institutional frameworks governing research involving human subjects.

Although individual anglers – people who fish recreationally – generally take small numbers of fish, collectively, a large number of them can have a substantial impact on the overall stock.

A profusion of biotechnology products is expected over the next five to 10 years, and the number and diversity of new products has the potential to overwhelm the U.S. regulatory system, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Hepatitis B and C kill more than 20,000 people every year in the United States.

The end of a roadside guardrail must be designed so that it is not a hazard to occupants of a vehicle striking it and so that it absorbs energy in a crash and redirects the vehicle into a safe trajectory.

A new report from the National Academies of Sciences, Engineering, and Medicine offers detailed recommendations to guide federal statistical agencies in creating a new entity that would enable them to combine data from multiple sources in order to provide more relevant, timely, and detailed statistics – for example, on the unemployment rate or the rate of violent crime.

Our ability to observe and predict severe weather events and other disasters has improved markedly over recent decades, yet this progress does not always translate into similar advances in the systems used in such circumstances to protect lives.

Policymakers’ efforts to reduce threats from improvised explosive devices (IEDs) should include greater oversight of precursor chemicals sold at the retail level – especially over the Internet – that terrorists, violent extremists, or criminals use to make homemade explosives, says a new report from the National Academies of Sciences, Engineering, and Medicine.

NASA, the National Oceanic and Atmospheric Administration (NOAA), and the United States Geological Survey (USGS) should implement a coordinated approach for their space-based environmental observations to further advance Earth science and applications for the next decade, says a new report by the National Academies of Sciences, Engineering, and Medicine.